Advancing the Science of Study Endpoints

Examine global strategies for selecting study endpoints and the impact of endpoints during the analysis of clinical evidence for various types of drug approval processes.

Back to Agenda

Session 7: Clinical Trial Grade Wearables – The Current State of the Science

Session Chair(s)

Keith Wenzel

Volunteer, DIA Study Endpoints Community, United States

A moderated discussion including audience questions and participation on the valid use of wearables in clinical trials, focusing on identification of valid devices and validation of clinical endpoints derived from wearable data.

Speaker(s)

Session Co-Chair

Bill Byrom, PhD

Vice President, Product Intelligence and Positioning; Principal, eCOA Science, Signant Health , United Kingdom

Moderator

Chad Gwaltney, PhD

President, Gwaltney Consulting, United States

Panelist

Elektra Papadopoulos, MD, MPH

Director, Patient Experience Data and Strategy, AbbVie, United States

Panelist

Robert Alan Vigersky, MD, FACP

Medical Director, Medtronic, United States

Panelist

Robert DiCicco, PharmD

Vice President, Portfolio Management, TransCelerate Biopharma Inc., United States

Have an account?

Advancing the Science of Study Endpoints

Session 7: Clinical Trial Grade Wearables – The Current State of the Science

Session Chair(s)

Keith Wenzel

Speaker(s)

Be informed and stay engaged.